肺ドラッグデリバリーシステムの世界市場規模調査＆予測、製品別、用途別（喘息、慢性閉塞性肺疾患、嚢胞性線維症）、流通チャネル別、地域別分析、2022-2029年

肺ドラッグデリバリーシステムの世界市場は、2021年に約466億1,307万米ドルとなり、予測期間2022-2029年には6.80%以上の健全な成長率で成長すると予測されています。

肺ドラッグデリバリーシステムは、吸入によって肺に直接薬剤を送り込むために使用されるデバイスです。これらのデバイスは、喘息、慢性閉塞性肺疾患（COPD）、嚢胞性線維症などの呼吸器疾患の治療に一般的に使用されています。したがって、世界の肺ドラッグデリバリーシステム市場の主な促進要因は、呼吸器疾患の有病率の増加、ヘルスケア支出の増加、個別化医療に対する需要の高まりです。さらに、技術の進歩や政府の取り組みが、予測期間2022年から2029年にかけて、市場に有利な成長機会を生み出しています。

米国FDAは、新しい肺ドラッグデリバリーシステムの開発を奨励する取り組みを行っています。2019年、FDAは産業界向けに吸入薬品の開発に関するガイダンス文書を発行しました。この文書では、臨床試験の設計、試験管内試験法の使用、および製品開発のその他の側面に関する推奨事項が示されています。同様に、2020年には、欧州医薬品庁（EMA）が吸入製剤の開発に関するリフレクションペーパーを発行しています。このペーパーは、製品設計、製剤、臨床試験デザインなどの問題について、医薬品開発者にガイダンスを提供しています。しかし、肺ドラッグデリバリーシステムの高コストが、2022-2029年の予測期間を通じて市場成長を阻害しています。

肺ドラッグデリバリーシステムの世界市場調査において考慮された主要地域は、アジア太平洋地域、北米、欧州、ラテンアメリカ、その他の地域です。北米は、喘息やCOPDなどの呼吸器系疾患の有病率が高いことに加え、確立されたヘルスケアインフラが存在し、医療費の水準が高いことから、肺ドラッグデリバリーシステム市場で最大のシェアを占めると予測されます。アジア太平洋地域は、医療費の増加、可処分所得の増加、呼吸器疾患に対する意識の高まりなどの要因により、肺ドラッグデリバリーシステム市場で最も速い成長を遂げると予想されています。また、この地域は人口が多く、呼吸器系疾患の負担が大きいことも、市場成長に寄与すると予想されます。

本調査の目的は、近年におけるさまざまなセグメントと国の市場規模を定義し、今後数年間の値を予測することです。本レポートは、調査対象国の産業の質的・量的な側面を取り入れるよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題など、重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場での潜在的な機会も組み込んでいます。.

目次

第1章 エグゼクティブサマリー

• マーケットスナップショット
• 世界市場・セグメント別市場推計・予測、2019年～2029年
  • 肺ドラッグデリバリーシステム市場、地域別、2019年～2029年
  • 肺ドラッグデリバリーシステム市場：製品別、2019年～2029年
  • 肺ドラッグデリバリーシステム市場：用途別、2019年-2029年
  • 肺ドラッグデリバリーシステム市場：流通チャネル別、2019年～2029年
• 主な動向
• 予測手法
• 調査の前提条件

第2章 肺薬剤デリバリーシステムの世界市場の定義と範囲

• 調査目的
• 市場の定義とスコープ
  • 調査対象範囲
  • 産業の進化
• 調査対象年
• 通貨換算レート

第3章 肺ドラッグデリバリーシステムの世界市場力学

• 肺ドラッグデリバリーシステム市場のインパクト分析（2019年～2029年）
  • 市場促進要因
    • 呼吸器疾患の有病率の増加
    • ヘルスケア支出の増加
    • 個別化医療への需要の高まり
  • 市場の課題
    • 肺ドラッグデリバリーシステムの高コスト化
  • 市場機会
    • 技術的進歩
    • 政府の取り組み

第4章 肺ドラッグデリバリーシステムの世界市場産業分析

• ポーターの5フォースモデル
  • 供給企業の交渉力
  • 買い手の交渉力
  • 新規参入業者の脅威
  • 代替品の脅威
  • 競争企業間の敵対関係
• ポーターの5フォースモデルの未来的アプローチ（2019年～2029年）
• PEST分析
  • 政治的
  • 経済的
  • 社会的
  • 技術的
• 投資採用モデル
• アナリストの結論・提言
• トップクラスの投資機会
• 主要成功戦略

第5章 リスクアセスメント：COVID-19のインパクト

• COVID-19が業界に与える全体的な影響についてのアセスメント
• COVID-19以前とCOVID-19以後の市場シナリオ

第6章 肺ドラッグデリバリーシステムの世界市場：製品別

• 市場スナップショット
• 肺ドラッグデリバリーシステムの世界市場：製品別、性能-ポテンシャル分析
• 肺ドラッグデリバリーシステムの世界市場、製品別推定・予測2019-2029年
• 肺ドラッグデリバリーシステム市場、サブセグメント別分析
  • ドライパウダー吸入器
  • 定量吸入器とネブライザー

第7章 肺ドラッグデリバリーシステムの世界市場：用途別

• 市場スナップショット
• 肺ドラッグデリバリーシステムの世界市場：用途別、性能-ポテンシャル分析
• 肺ドラッグデリバリーシステムの世界市場、用途別推定・予測2019-2029
• 肺ドラッグデリバリーシステム市場、サブセグメント別分析
  • 気管支喘息
  • 慢性閉塞性肺疾患（COPD）
  • 嚢胞性線維症（Cystic Fibrosis

第8章 肺ドラッグデリバリーシステムの世界市場：流通チャネル別

• 市場スナップショット
• 肺ドラッグデリバリーシステムの世界市場：流通チャネル別、実績 - ポテンシャル分析
• 肺ドラッグデリバリーシステムの世界市場：流通チャネル別推定・予測2019-2029
• 肺薬剤デリバリーシステム市場、サブセグメント別分析
  • 小売薬局
  • 病院薬局
  • eコマース

第9章 肺ドラッグデリバリーシステムの世界市場：地域別分析

• 肺ドラッグデリバリーシステム市場、地域別市場スナップショット
• 北米
  • 米国
    • 製品別の推定・予測、2019年～2029年
    • 用途別の推定・予測、2019年～2029年
    • 流通チャネル別の推定・予測、2019年～2029年
  • カナダ
• 欧州肺ドラッグデリバリーシステム市場スナップショット
  • 英国
  • ドイツ
  • フランス
  • スペイン
  • イタリア
  • その他欧州
• アジア太平洋の肺ドラッグデリバリーシステム市場スナップショット
  • 中国
  • インド
  • 日本
  • オーストラリア
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカの肺ドラッグデリバリーシステム市場スナップショット
  • ブラジル
  • メキシコ
• 世界のその他の地域

第10章 競合情報

• トップ市場戦略
• 企業プロファイル
  • AstraZeneca PLC
    • 主要情報
    • 概要
    • 財務（データの入手が可能な場合のみ）
    • 製品概要
    • 最近の開発状況
  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Novartis AG
  • Koninklijke Philips N.V.
  • 3M company
  • Janssen（Johnson & Johnson）
  • Clement Clarke International
  • Briggs Healthcare
  • Aerogen

第11章 調査プロセス

• 調査プロセス
  • データマイニング
  • 分析
  • 市場推定
  • バリデーション
  • 出版
• 調査の特徴
• 調査の前提条件

LIST OF TABLES

• TABLE 1. Global Pulmonary Drug Delivery Systems Market, report scope
• TABLE 2. Global Pulmonary Drug Delivery Systems Market estimates & forecasts by Region 2019-2029 (USD Million)
• TABLE 3. Global Pulmonary Drug Delivery Systems Market estimates & forecasts by Product 2019-2029 (USD Million)
• TABLE 4. Global Pulmonary Drug Delivery Systems Market estimates & forecasts by Application 2019-2029 (USD Million)
• TABLE 5. Global Pulmonary Drug Delivery Systems Market estimates & forecasts by Distribution Channel 2019-2029 (USD Million)
• TABLE 6. Global Pulmonary Drug Delivery Systems Market by segment, estimates & forecasts, 2019-2029 (USD Million)
• TABLE 7. Global Pulmonary Drug Delivery Systems Market by region, estimates & forecasts, 2019-2029 (USD Million)
• TABLE 8. Global Pulmonary Drug Delivery Systems Market by segment, estimates & forecasts, 2019-2029 (USD Million)
• TABLE 9. Global Pulmonary Drug Delivery Systems Market by region, estimates & forecasts, 2019-2029 (USD Million)
• TABLE 10. Global Pulmonary Drug Delivery Systems Market by segment, estimates & forecasts, 2019-2029 (USD Million)
• TABLE 11. Global Pulmonary Drug Delivery Systems Market by region, estimates & forecasts, 2019-2029 (USD Million)
• TABLE 12. Global Pulmonary Drug Delivery Systems Market by segment, estimates & forecasts, 2019-2029 (USD Million)
• TABLE 13. Global Pulmonary Drug Delivery Systems Market by region, estimates & forecasts, 2019-2029 (USD Million)
• TABLE 14. Global Pulmonary Drug Delivery Systems Market by segment, estimates & forecasts, 2019-2029 (USD Million)
• TABLE 15. Global Pulmonary Drug Delivery Systems Market by region, estimates & forecasts, 2019-2029 (USD Million)
• TABLE 16. U.S. Pulmonary Drug Delivery Systems Market estimates & forecasts, 2019-2029 (USD Million)
• TABLE 17. U.S. Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 18. U.S. Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 19. Canada Pulmonary Drug Delivery Systems Market estimates & forecasts, 2019-2029 (USD Million)
• TABLE 20. Canada Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 21. Canada Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 22. UK Pulmonary Drug Delivery Systems Market estimates & forecasts, 2019-2029 (USD Million)
• TABLE 23. UK Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 24. UK Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 25. Germany Pulmonary Drug Delivery Systems Market estimates & forecasts, 2019-2029 (USD Million)
• TABLE 26. Germany Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 27. Germany Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 28. France Pulmonary Drug Delivery Systems Market estimates & forecasts, 2019-2029 (USD Million)
• TABLE 29. France Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 30. France Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 31. Italy Pulmonary Drug Delivery Systems Market estimates & forecasts, 2019-2029 (USD Million)
• TABLE 32. Italy Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 33. Italy Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 34. Spain Pulmonary Drug Delivery Systems Market estimates & forecasts, 2019-2029 (USD Million)
• TABLE 35. Spain Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 36. Spain Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 37. RoE Pulmonary Drug Delivery Systems Market estimates & forecasts, 2019-2029 (USD Million)
• TABLE 38. RoE Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 39. RoE Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 40. China Pulmonary Drug Delivery Systems Market estimates & forecasts, 2019-2029 (USD Million)
• TABLE 41. China Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 42. China Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 43. India Pulmonary Drug Delivery Systems Market estimates & forecasts, 2019-2029 (USD Million)
• TABLE 44. India Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 45. India Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 46. Japan Pulmonary Drug Delivery Systems Market estimates & forecasts, 2019-2029 (USD Million)
• TABLE 47. Japan Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 48. Japan Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 49. South Korea Pulmonary Drug Delivery Systems Market estimates & forecasts, 2019-2029 (USD Million)
• TABLE 50. South Korea Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 51. South Korea Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 52. Australia Pulmonary Drug Delivery Systems Market estimates & forecasts, 2019-2029 (USD Million)
• TABLE 53. Australia Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 54. Australia Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 55. RoAPAC Pulmonary Drug Delivery Systems Market estimates & forecasts, 2019-2029 (USD Million)
• TABLE 56. RoAPAC Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 57. RoAPAC Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 58. Brazil Pulmonary Drug Delivery Systems Market estimates & forecasts, 2019-2029 (USD Million)
• TABLE 59. Brazil Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 60. Brazil Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 61. Mexico Pulmonary Drug Delivery Systems Market estimates & forecasts, 2019-2029 (USD Million)
• TABLE 62. Mexico Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 63. Mexico Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 64. RoLA Pulmonary Drug Delivery Systems Market estimates & forecasts, 2019-2029 (USD Million)
• TABLE 65. RoLA Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 66. RoLA Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 67. Row Pulmonary Drug Delivery Systems Market estimates & forecasts, 2019-2029 (USD Million)
• TABLE 68. Row Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 69. Row Pulmonary Drug Delivery Systems Market estimates & forecasts by segment 2019-2029 (USD Million)
• TABLE 70. List of secondary sources, used in the study of global Pulmonary Drug Delivery Systems Market
• TABLE 71. List of primary sources, used in the study of global Pulmonary Drug Delivery Systems Market
• TABLE 72. Years considered for the study
• TABLE 73. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

List of figures

• FIG 1. Global Pulmonary Drug Delivery Systems Market, research methodology
• FIG 2. Global Pulmonary Drug Delivery Systems Market, Market estimation techniques
• FIG 3. Global Market size estimates & forecast methods
• FIG 4. Global Pulmonary Drug Delivery Systems Market, key trends 2021
• FIG 5. Global Pulmonary Drug Delivery Systems Market, growth prospects 2022-2029
• FIG 6. Global Pulmonary Drug Delivery Systems Market, porters 5 force model
• FIG 7. Global Pulmonary Drug Delivery Systems Market, pest analysis
• FIG 8. Global Pulmonary Drug Delivery Systems Market, value chain analysis
• FIG 9. Global Pulmonary Drug Delivery Systems Market by segment, 2019 & 2029 (USD Million)
• FIG 10. Global Pulmonary Drug Delivery Systems Market by segment, 2019 & 2029 (USD Million)
• FIG 11. Global Pulmonary Drug Delivery Systems Market by segment, 2019 & 2029 (USD Million)
• FIG 12. Global Pulmonary Drug Delivery Systems Market by segment, 2019 & 2029 (USD Million)
• FIG 13. Global Pulmonary Drug Delivery Systems Market by segment, 2019 & 2029 (USD Million)
• FIG 14. Global Pulmonary Drug Delivery Systems Market, regional snapshot 2019 & 2029
• FIG 15. North America Pulmonary Drug Delivery Systems Market 2019 & 2029 (USD Million)
• FIG 16. Europe Pulmonary Drug Delivery Systems Market 2019 & 2029 (USD Million)
• FIG 17. Asia pacific Pulmonary Drug Delivery Systems Market 2019 & 2029 (USD Million)
• FIG 18. Latin America Pulmonary Drug Delivery Systems Market 2019 & 2029 (USD Million)
• FIG 19. Global Pulmonary Drug Delivery Systems Market, company Market share analysis (2021)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

Global Pulmonary Drug Delivery Systems Market is valued approximately USD 46613.07 million in 2021 and is anticipated to grow with a healthy growth rate of more than 6.80% over the forecast period 2022-2029. Pulmonary drug delivery systems are devices that are used to deliver medication directly to the lungs through inhalation. These devices are commonly used to treat respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Thus, the major driving factors for the Global Pulmonary Drug Delivery Systems Market are increasing prevalence of respiratory diseases, increasing healthcare expenditure and growing demand for personalized medicine. Moreover, technological advancements and government initiatives is creating lucrative growth opportunity for the market over the forecast period 2022-2029.

The US FDA has been working to encourage the development of new pulmonary drug delivery systems. In 2019, the FDA issued a guidance document for industry on the development of inhaled drug products. The document provides recommendations on the design of clinical trials, the use of in vitro testing methods, and other aspects of product development. Similarly, in 2020, the European Medicines Agency (EMA) issued a reflection paper on the development of inhalation products. The paper provides guidance to drug developers on issues such as product design, formulation, and clinical trial design. However, the high cost of Pulmonary Drug Delivery Systems stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Pulmonary Drug Delivery Systems Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is expected to hold the largest share of the pulmonary drug delivery systems market due to the high prevalence of respiratory diseases such as asthma and COPD in the region, as well as the presence of well-established healthcare infrastructure and high levels of healthcare expenditure. The Asia-Pacific region is expected to experience the fastest growth in the pulmonary drug delivery systems market, driven by factors such as increasing healthcare expenditure, rising disposable incomes, and increasing awareness of respiratory diseases. In addition, the region's large population and high burden of respiratory diseases are expected to contribute to market growth.

Major market players included in this report are:

• AstraZeneca plc
• Boehringer Ingelheim GmbH
• GlaxoSmithKline plc
• Novartis AG
• Koninklijke Philips N.V.
• 3M company
• Janssen (Johnson & Johnson)
• Clement Clarke International
• Briggs Healthcare
• Aerogen

Recent Developments in the Market:

• In 2019, AstraZeneca launched its Bevespi Aerosphere, a dual-bronchodilator inhaler, for the treatment of chronic obstructive pulmonary disease (COPD) in the US market. The company also collaborated with Breath Therapeutics in 2019 to develop inhaled therapies for patients with pulmonary disease.
• In 2020, GlaxoSmithKline received FDA approval for its Nucala autoinjector for the treatment of severe asthma. The company also announced a partnership with Verona Pharma in 2020 to develop a nebulized therapy for the treatment of respiratory diseases.

Global Pulmonary Drug Delivery Systems Market Report Scope:

• Historical Data: 2019-2020-2021
• Base Year for Estimation: 2021
• Forecast period: 2022-2029
• Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
• Segments Covered: Product, Application, Distribution Channel, Region
• Regional Scope: North America; Europe; Asia Pacific; Latin America; Rest of the World
• Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Product:

• Dry Powder Inhaler
• Metered Dose Inhaler and Nebulizers

By Application:

• Asthma
• Chronic Obstructive Pulmonary Diseases (COPD)
• Cystic Fibrosis

By Distribution Channel:

• Retail Pharmacies
• Hospital Pharmacies
• E-Commerce

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Rest of the World

Table of Contents

Chapter 1. Executive Summary

• 1.1. Market Snapshot
• 1.2. Global & Segmental Market Estimates & Forecasts, 2019-2029 (USD Million)
  • 1.2.1. Pulmonary Drug Delivery Systems Market, by Region, 2019-2029 (USD Million)
  • 1.2.2. Pulmonary Drug Delivery Systems Market, by Product, 2019-2029 (USD Million)
  • 1.2.3. Pulmonary Drug Delivery Systems Market, by Application, 2019-2029 (USD Million)
  • 1.2.4. Pulmonary Drug Delivery Systems Market, by Distribution Channel, 2019-2029 (USD Million)
• 1.3. Key Trends
• 1.4. Estimation Methodology
• 1.5. Research Assumption

Chapter 2. Global Pulmonary Drug Delivery Systems Market Definition and Scope

• 2.1. Objective of the Study
• 2.2. Market Definition & Scope
  • 2.2.1. Scope of the Study
  • 2.2.2. Industry Evolution
• 2.3. Years Considered for the Study
• 2.4. Currency Conversion Rates

Chapter 3. Global Pulmonary Drug Delivery Systems Market Dynamics

• 3.1. Pulmonary Drug Delivery Systems Market Impact Analysis (2019-2029)
  • 3.1.1. Market Drivers
    • 3.1.1.1. Increasing prevalence of respiratory diseases
    • 3.1.1.2. Increasing healthcare expenditure
    • 3.1.1.3. Growing demand for personalized medicine
  • 3.1.2. Market Challenges
    • 3.1.2.1. High Cost of Pulmonary Drug Delivery Systems
  • 3.1.3. Market Opportunities
    • 3.1.3.1. Technological advancements
    • 3.1.3.2. Government initiatives

Chapter 4. Global Pulmonary Drug Delivery Systems Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
• 4.2. Futuristic Approach to Porter's 5 Force Model (2019-2029)
• 4.3. PEST Analysis
  • 4.3.1. Political
  • 4.3.2. Economical
  • 4.3.3. Social
  • 4.3.4. Technological
• 4.4. Investment Adoption Model
• 4.5. Analyst Recommendation & Conclusion
• 4.6. Top investment opportunity
• 4.7. Top winning strategies

Chapter 5. Risk Assessment: COVID-19 Impact

• 5.1. Assessment of the overall impact of COVID-19 on the industry
• 5.2. Pre COVID-19 and post COVID-19 Market scenario

Chapter 6. Global Pulmonary Drug Delivery Systems Market, by Product

• 6.1. Market Snapshot
• 6.2. Global Pulmonary Drug Delivery Systems Market by Product, Performance - Potential Analysis
• 6.3. Global Pulmonary Drug Delivery Systems Market Estimates & Forecasts by Product 2019-2029 (USD Million)
• 6.4. Pulmonary Drug Delivery Systems Market, Sub Segment Analysis
  • 6.4.1. Dry Powder Inhaler
  • 6.4.2. Metered Dose Inhaler and Nebulizers

Chapter 7. Global Pulmonary Drug Delivery Systems Market, by Application

• 7.1. Market Snapshot
• 7.2. Global Pulmonary Drug Delivery Systems Market by Application, Performance - Potential Analysis
• 7.3. Global Pulmonary Drug Delivery Systems Market Estimates & Forecasts by Application 2019-2029 (USD Million)
• 7.4. Pulmonary Drug Delivery Systems Market, Sub Segment Analysis
  • 7.4.1. Asthma
  • 7.4.2. Chronic Obstructive Pulmonary Diseases (COPD)
  • 7.4.3. Cystic Fibrosis

Chapter 8. Global Pulmonary Drug Delivery Systems Market, by Distribution Channel

• 8.1. Market Snapshot
• 8.2. Global Pulmonary Drug Delivery Systems Market by Distribution Channel, Performance - Potential Analysis
• 8.3. Global Pulmonary Drug Delivery Systems Market Estimates & Forecasts by Distribution Channel 2019-2029 (USD Million)
• 8.4. Pulmonary Drug Delivery Systems Market, Sub Segment Analysis
  • 8.4.1. Retail Pharmacies
  • 8.4.2. Hospital Pharmacies
  • 8.4.3. E-Commerce

Chapter 9. Global Pulmonary Drug Delivery Systems Market, Regional Analysis

• 9.1. Pulmonary Drug Delivery Systems Market, Regional Market Snapshot
• 9.2. North America Pulmonary Drug Delivery Systems Market
  • 9.2.1. U.S. Pulmonary Drug Delivery Systems Market
    • 9.2.1.1. Product breakdown estimates & forecasts, 2019-2029
    • 9.2.1.2. Application breakdown estimates & forecasts, 2019-2029
    • 9.2.1.3. Distribution Channel breakdown estimates & forecasts, 2019-2029
  • 9.2.2. Canada Pulmonary Drug Delivery Systems Market
• 9.3. Europe Pulmonary Drug Delivery Systems Market Snapshot
  • 9.3.1. U.K. Pulmonary Drug Delivery Systems Market
  • 9.3.2. Germany Pulmonary Drug Delivery Systems Market
  • 9.3.3. France Pulmonary Drug Delivery Systems Market
  • 9.3.4. Spain Pulmonary Drug Delivery Systems Market
  • 9.3.5. Italy Pulmonary Drug Delivery Systems Market
  • 9.3.6. Rest of Europe Pulmonary Drug Delivery Systems Market
• 9.4. Asia-Pacific Pulmonary Drug Delivery Systems Market Snapshot
  • 9.4.1. China Pulmonary Drug Delivery Systems Market
  • 9.4.2. India Pulmonary Drug Delivery Systems Market
  • 9.4.3. Japan Pulmonary Drug Delivery Systems Market
  • 9.4.4. Australia Pulmonary Drug Delivery Systems Market
  • 9.4.5. South Korea Pulmonary Drug Delivery Systems Market
  • 9.4.6. Rest of Asia Pacific Pulmonary Drug Delivery Systems Market
• 9.5. Latin America Pulmonary Drug Delivery Systems Market Snapshot
  • 9.5.1. Brazil Pulmonary Drug Delivery Systems Market
  • 9.5.2. Mexico Pulmonary Drug Delivery Systems Market
• 9.6. Rest of The World Pulmonary Drug Delivery Systems Market

Chapter 10. Competitive Intelligence

• 10.1. Top Market Strategies
• 10.2. Company Profiles
  • 10.2.1. AstraZeneca PLC
    • 10.2.1.1. Key Information
    • 10.2.1.2. Overview
    • 10.2.1.3. Financial (Subject to Data Availability)
    • 10.2.1.4. Product Summary
    • 10.2.1.5. Recent Developments
  • 10.2.2. Boehringer Ingelheim GmbH
  • 10.2.3. GlaxoSmithKline plc
  • 10.2.4. Novartis AG
  • 10.2.5. Koninklijke Philips N.V.
  • 10.2.6. 3M company
  • 10.2.7. Janssen (Johnson & Johnson)
  • 10.2.8. Clement Clarke International
  • 10.2.9. Briggs Healthcare
  • 10.2.10. Aerogen

Chapter 11. Research Process

• 11.1. Research Process
  • 11.1.1. Data Mining
  • 11.1.2. Analysis
  • 11.1.3. Market Estimation
  • 11.1.4. Validation
  • 11.1.5. Publishing
• 11.2. Research Attributes
• 11.3. Research Assumption